The prevalence and clinical features associated of hypothyroidism among Thai systemic sclerosis patients

Yathao Paolee¹, Chingching Foocharoen¹✉, Suranut Charoensri³, Mayfong Mayxay², Ajanee Mahakkanukrauh¹, Siraphop Suwannaroj¹ & Ratanavadee Nanagara¹

Thyroid disease, particularly hypothyroidism, has been reported in systemic sclerosis (SSc). Some clinical features of SSc can also present in hypothyroidism. Our aims were to determine the prevalence of, and describe clinical features associated with, hypothyroidism in SSc patients. We conducted a historical cohort study of adult SSc patients who underwent screening thyroid function tests at the Scleroderma Clinic, Khon Kaen University, Thailand, between 2009 and 2018. The patients who had any thyroid disorders before the onset of SSc and were diagnosed as an overlap syndrome were excluded. A total of 200 SSc were included according to sample size calculation, among whom the female to male ratio was 2:1. The majority of cases (137; 69.5%) were diffuse cutaneous SSc subset. The mean age was 55.8 ± 10.7 years and the median duration of disease 4.9 (IQR 1.6–9.9) years. Of the total, 9 had primary hypothyroidism (prevalence 4.5%; 95%CI 2.1–8.4) and 22 had subclinical hypothyroidism (prevalence 11%; 95%CI 7.0–16.2). Of the latter 22, 71% had dcSSc. Logistic regression analysis indicated that unexplained anemia was significantly associated with either subclinical hypothyroid or hypothyroidism (OR 2.74; 95% CI 1.17–6.47), whereas Raynaud’s phenomenon had a negative association (OR 0.28; 95% CI 0.11–0.66). Neither severity of skin tightness nor internal organ involvement were associated with hypothyroidism among SSc patients. Clinical-subclinical hypothyroidism is uncommon among SSc patients, it is frequently associated with anemia, and less so Raynaud’s phenomenon. Clinical-subclinical hypothyroidism should thus be considered in cases of unexplained anemia in SSc patients.

Systemic sclerosis (SSc) is a connective tissue disease of unknown cause and complex pathogenesis. The disease includes 4 hallmarks: (a) auto-immunity, (b) inflammation, (c) functional and structural alterations in small blood vessels, and (d) widespread interstitial and vascular fibrosis affecting multiple organ systems. SSc seemingly confined to the skin, also involves visceral organs (kidneys, lungs, heart, and gastrointestinal tract) and trends to have significant morbidity and mortality for patients with SSc1,2.

Endocrine dysfunction can complicate the treatment process of patients with SSc. The most common endocrine problem associated with SSc is thyroid disease, and the frequency of other endocrine disorders is similar to that of the general population3. Several studies have documented that thyroid disease occurs in 10% to 14% of patients with SSc due to severe fibrosis of the thyroid gland1,4–6. Autoimmune regulator gene polymorphism has been linked to SSc in association with Hashimoto’s thyroiditis, and autoimmune thyroid disease seems to be associated with a higher index level of anti-Scl707,8. A previous study revealed that SSc patients with diffuse cutaneous systemic sclerosis (dcSSc) had higher thyroid stimulating hormone (TSH) serum levels than that in patients with limited cutaneous systemic sclerosis (lcSSc). The TSH level was higher in SSc patients the more severe the skin disease, and TSH level was significantly correlated the higher the modified Rodnan’s skin score (mRSS) (p < 0.001 and r² = 0.32) compared to those with normal TSH serum levels9.

Several studies have illustrated the high incidence and prevalence of new cases of hypothyroidism among SSc patients. Those studies demonstrated a close association between hypothyroidism in SSc and subcutaneous calcinosis, Raynaud’s phenomenon (RP), esophageal hypomotility, sclerodactyly, and multiple telangiectasia3,9.

¹Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. ²Lao-Oxford-Mahosot Hospital-Wellcome Trust-Research Unit, Mahosot Hospital, University of Health Sciences of Laos, Vientiane, Laos. ✉email: fching@kku.ac.th
Shahin et al. found that an overall decrease in free thyroxin (FT4) levels among SSc patients with disease duration under 3 years correlated significantly with the DLCO level \((r = +0.90, p < 0.01)\), while the FT4 level was significantly correlated to restricted motion of hand joints \((r = 0.66, p < 0.01)\) in SSc patients with a disease duration over 3 years and having hypothyroidism\(^{10}\). Toki et al. showed the prevalence of anti-centromere antibody positivity and severe facial skin sclerosis among female SSc patients was significantly associated with the presence of autoimmune thyroiditis (AITD)\(^3\).

In clinical practice, the current recommendation for monitoring thyroid function in SSc patients is inconsistent. The aims of the current study were to determine the prevalence of hypothyroidism in Thai SSc and to describe clinical features of SSc associated with hypothyroidism.

### Materials and methods

This was a historical cohort study that included adult participants over 18 diagnosed with SSc at the Scleroderma Clinic, Khon Kaen University, Thailand, between 2009 and 2018. Evaluations (including thyroid function tests) were stored in the Scleroderma cohort database. We excluded participants diagnosed with any thyroid disorders before onset of SSc and the patients who were diagnosed SSc overlap with other connective tissue diseases.

A diagnosis of SSc was based on the criteria from the American Rheumatology Association (ARA) 1980 or the American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) 2013 Classification Criteria of SSc\(^{11,12}\). Duration of disease was based on the duration from onset of first non-Raynaud’s phenomenon symptom to the date of the thyroid function test. Table 1 shows the definition of clinical parameters determined from medical records and the criteria for diagnosis of thyroid status.

### Sample size.

The sample size was calculated in light of the previous prevalence of hypothyroidism reported in the literature. The prevalence of hypothyroidism in SSc was 10–14% \(^3\)–\(^6\). To determine the primary outcome of the study with 95% power at a significance level of 0.05, the sample size needed to be 183. We thus included 200 patients into the study.

### Statistical analysis.

The data were described using frequencies and percentages. The prevalence of hypothyroidism in SSc was described with its 95% confidence interval (95%CI). Exploratory univariable analysis was done using univariable logistic regression. The odds ratio (OR) with 95%CI and p-value were used to determine the association between SSc clinical characteristics and clinical or subclinical hypothyroidism. Multivariable logistic regression analysis was then performed to identify clinical association with clinical or subclinical hypothyroidism. The removal of non-contributing associated factors was based primarily on clinical relevancy and statistical significance. Clinical variables with OR closest to 1.00 and insignificant P value of > 0.1 were sequentially eliminated from multivariable logistic regression model\(^{13}\). A P-value <0.05 was considered statistically significant. All data analyses were performed using STATA version 16.0 (Stata Corp, College Station, TX).

The study was designed by the authors and approved by the Human Research Ethics Committee of Khon Kaen University per the Helsinki Declaration and the Good Clinical Practice Guidelines (HIE61156). All eligible patients signed informed consent before enrollment in the cohort study. The sponsor had no role in the study.

### Ethical consideration.

The Human Research Ethics Committee of Khon Kaen University reviewed and approved the study per the Helsinki Declaration and the Good Clinical Practice Guidelines (HIE61156).

### Consent for publication.

All of the authors consent to publishing and hereby grant the Publisher exclusive license of the full copyright.
Results

A total of 200 medical records of SSc patients tested for thyroid function were reviewed. The female to male ratio was 2:1. The majority of cases (137; 69.5%) had dcSSc. The mean age was 55.8 ± 10.7 years and the median duration of the disease was 4.9 (IQR 1.6–9.9) years. Of the total, 9 cases had primary hypothyroidism for a prevalence of 4.5% (95%CI 2.1–8.4) and 22 had subclinical hypothyroidism for a prevalence of 11% (95%CI 7.0–16.2). Three cases (1.5%; 95%CI 0.3–4.3) were diagnosed with either hyperthyroidism (2 cases) or subclinical hyperthyroidism (1 case). The prevalence of primary hypothyroidism and subclinical hypothyroidism among Thai SSc patients was 15.5% (95%CI 10.8–21.3). Of the patients who had either hypothyroidism or subclinical hypothyroidism, 22 cases (71%) had the dcSSc subset, and 13 (41.9%) had a disease duration under 4 years. Two cases (6.5%) had a body mass index (BMI) under 18.5 kg/m².

Due to the low number of cases of both clinical and subclinical hyperthyroidism, we excluded the condition from the analysis and due to the low number of cases of primary and subclinical hypothyroidism, we combined them both into the clinical-subclinical hypothyroidism group. The clinical association of clinical-subclinical hypothyroidism among Thai SSc patients was 15.5% (95%CI 10.8–21.3). Of the patients who had either hypothyroidism or subclinical hypothyroidism, 22 cases (71%) had the dcSSc subset, and 13 (41.9%) had a disease duration under 4 years. Two cases (6.5%) had a body mass index (BMI) under 18.5 kg/m².

Due to the low number of cases of both clinical and subclinical hyperthyroidism, we excluded the condition from the analysis and due to the low number of cases of primary and subclinical hypothyroidism, we combined them both into the clinical-subclinical hypothyroidism group. The clinical association of clinical-subclinical hypothyroidism among Thai SSc patients was 15.5% (95%CI 10.8–21.3). Of the patients who had either hypothyroidism or subclinical hypothyroidism, 22 cases (71%) had the dcSSc subset, and 13 (41.9%) had a disease duration under 4 years. Two cases (6.5%) had a body mass index (BMI) under 18.5 kg/m².

Table 2. Clinical parameters associated with clinical-subclinical hypothyroidism. CI: confidence interval; dcSSc: diffuse cutaneous systemic sclerosis; BMI: body mass index; RP: Raynaud’s phenomenon; PAH: pulmonary arterial hypertension; ATA: anti-topoisomerase I antibody; ACA: anti-centromere antibody; FVC forced vital capacity; LVEF left ventricular ejection fraction; NA: data not available due to a statistical limitation. *Statistical significance;

| Data | Normal thyroid hormone N = 166 | Clinical–subclinical hypothyroidism N = 31 | Odds ratio (95%CI) | P-value |
|------|--------------------------------|------------------------------------------|--------------------|---------|
| Age at onset > 60 years | 26 (15.7) | 6 (19.4) | 1.30 (0.40–3.60) | 0.60 |
| Duration of disease ≤ 4 years, N (%) | 76 (45.8) | 13 (41.9) | 0.86 (0.36–2.00) | 0.84 |
| Female, N (%) | 107 (64.5) | 25 (80.6) | 2.30 (0.85–7.21) | 0.09 |
| dcSSc subset, N (%) | 115 (69.3) | 22 (70.9) | 1.08 (0.45–2.86) | 1.00 |
| BMI < 18.5 kg/m², N (%) | 14 (29.2) | 2 (28.5) | 0.97 (0.08–6.84) | 1.00 |
| mRSS > 20 points, N (%) | 17 (10.2) | 4 (12.9) | 1.3 (0.30–4.41) | 0.75 |

Clinical symptoms on the study date

| Rp, N (%) | 103 (62.2) | 9 (29.0) | 0.25 (0.09–0.61) | 0.001* |
| Digital ulcer, N (%) | 41 (24.7) | 5 (16.1) | 0.61 (0.17–1.79) | 0.36 |
| Digital gangrene, N (%) | 1 (0.6) | 0 | NA |
| Telangiectasia, N (%) | 36 (21.7) | 9 (29.0) | 1.5 (0.56–3.78) | 0.36 |
| Calcinosis cutis, N (%) | 5 (3.1) | 2 (6.4) | 2.19 (0.20–14.10) | 0.30 |
| Salt and pepper skin, N (%) | 66 (40.2) | 12 (38.7) | 0.93 (0.38–2.19) | 1.00 |
| Edematous skin, N (%) | 27 (16.5) | 7 (22.5) | 1.48 (0.49–1.98) | 0.44 |
| Tendon friction rub, N (%) | 22 (13.4) | 2 (6.4) | 0.44 (0.04–1.98) | 0.38 |
| Hand deformity, N (%) | 50 (30.5) | 10 (32.2) | 1.08 (0.42–2.62) | 0.83 |
| Arthritis, N (%) | 14 (8.5) | 2 (6.4) | 0.73 (0.07–3.50) | 1.00 |
| Muscle weakness, N (%) | 14 (8.5) | 0 | NA |
| Esophageal involvement, N (%) | 58 (35.4) | 13 (41.9) | 1.32 (0.55–3.08) | 0.54 |
| Stomach involvement, N (%) | 29 (17.7) | 6 (19.3) | 1.11 (0.34–3.13) | 0.80 |
| Constipation, N (%) | 30 (18.3) | 5 (16.1) | 0.85 (0.23–2.53) | 1.00 |
| Weight loss, N (%) | 45 (27.4) | 3 (9.6) | 0.28 (0.05–0.99) | 0.04* |
| Pulmonary fibrosis, N (%) | 66 (39.7) | 8 (25.8) | 0.52 (0.19–1.31) | 0.16 |
| PAH, N (%) | 14 (8.4) | 0 | NA |

Laboratory parameters

| ATA, N = 39 (%) | 31 of 34 (91.1) | 3 of 5 (60.0) | 0.14 (0.01–2.56) | 0.11 |
| ACA, N = 24 (%) | 1 of 24 (4.1) | 1 of 2 (50.0) | 23 (0.14–1877.70) | 0.15 |
| Anemia, N (%) | 76 (45.7) | 21 (67.7) | 2.48 (1.03–6.27) | 0.03* |
| FVC<70%, N (%) | 48 (55.1) | 5 (71.4) | 2.03 (0.30–22.20) | 0.46 |
| Pericardial effusion (present), N (%) | 14 (14.4) | 2 (14.2) | 0.98 (0.09–5.22) | 1.00 |
| LVEF (%)<50%, N (%) | 4 (4.0) | 0 | NA |
The presence of anemia was strongly associated with the presence of clinical-subclinical hypothyroidism among our Thai SSc patients. The patients who had anemia tended to have clinical-subclinical hypothyroidism 2.7 times more than those who had no anemia. Our finding agrees with previous studies. Kosenli et al. reported the prevalence of anemia in the hypothyroidism group was 43%, subclinical hypothyroidism group 39%, vs. 26% in the control group. The prevalence of anemia in both the hypothyroidism group and subclinical hypothyroidism group was significantly higher than in the control group (p = 0.003 and p = 0.021, respectively). The association between hypothyroidism and anemia has been postulated as being due to absent or insufficient thyroid hormones for erythropoiesis stimulation\textsuperscript{19}. Anemia due to erythropoietin insufficiency or deficiency is normochromic normocytic anemia. The anemia in hypothyroidism should then be normochromic normocytic\textsuperscript{20}; however, normocytic, hypochromic-microcytic, or macrocytic anemia have all been reported in hypothyroidism\textsuperscript{21}. Clinical-subclinical hypothyroidism should thus be considered in cases of unexplained anemia in SSc patients and a thyroid function test should be done to evaluate such patients.

The prevalence of RP was inversely associated with clinical-subclinical hypothyroidism in our SSc patients. Not only RP but also other signs of vasculopathy. In particular, digital ulcer, digital gangrene, and PAH were less frequently observed in SSc with clinical-subclinical hypothyroidism than among those with a normal thyroid function test. Since none of the patients with clinical-subclinical hypothyroidism had digital gangrene or PAH, there was a statistical limitation to determine a negative association between vasculopathy and clinical-subclinical hypothyroidism. Nevertheless, the negative association between vasculopathy and hypothyroidism in our study contrasts with other studies in which the presence of RP was found in those who had hypothyroidism. Most reports are case reports and do not include SSc patients. This is because RP has been reported in patients with hypothyroidism and symptoms disappeared after thyroid replacement therapy\textsuperscript{22-24}. RP with Graves’ disease has been reported as a presentation of lcSSc for many years before lcSSc was diagnosed\textsuperscript{25}. Withrington et al. also reported a patient with a diagnosis of mixed connective tissue disease and that RP developed hypothyroidism 15 months later\textsuperscript{26}. There is also a case report of a patient who presented with clinical myocardial infarction but a normal coronary angiogram showed coexisting RP and thyroid deficiency\textsuperscript{27}. Until recently, the association between RP and thyroid disease was uncertain. Due to the low prevalence of hypothyroidism in our study might be ethnic differences or genetic factors\textsuperscript{16}. The presence of anemia was strongly associated with the presence of clinical-subclinical hypothyroidism among our Thai SSc patients. The patients who had anemia tended to have clinical-subclinical hypothyroidism 2.7 times more than those who had no anemia. Our finding agrees with previous studies. Kosenli et al. reported the prevalence of anemia in the hypothyroidism group was 43%, subclinical hypothyroidism group 39%, vs. 26% in the control group. The prevalence of anemia in both the hypothyroidism group and subclinical hypothyroidism group was significantly higher than in the control group (p = 0.003 and p = 0.021, respectively). The association between hypothyroidism and anemia has been postulated as being due to absent or insufficient thyroid hormones for erythropoiesis stimulation\textsuperscript{19}. Anemia due to erythropoietin insufficiency or deficiency is normochromic normocytic anemia. The anemia in hypothyroidism should then be normochromic normocytic\textsuperscript{20}; however, normocytic, hypochromic-microcytic, or macrocytic anemia have all been reported in hypothyroidism\textsuperscript{21}. Clinical-subclinical hypothyroidism should thus be considered in cases of unexplained anemia in SSc patients and a thyroid function test should be done to evaluate such patients.

**Discussion**

Thyroid disease is uncommon in SSc. According to our observations, 34 cases (17%) of our patients had an abnormal thyroid function test, of whom 1% had hyperthyroidism, 0.5% had subclinical hyperthyroidism, 4.5% had hypothyroidism, and 11% had subclinical hypothyroidism. The prevalence of hypothyroidism among our SSc patients was less than that in previous studies, where the prevalence of primary hypothyroidism was between 10 and 14% in SSc (13.8% in Japan\textsuperscript{3}, 10–14% in the United States\textsuperscript{4,5}, and 9.4% in New Zealand\textsuperscript{6}). The difference in prevalence might be explained by differences in the mean age of participants among the studies. The mean age of our participants was 55.8 ± 10.7 years vs. 64.9 ± 0.7 years in a previous study\textsuperscript{3}. Generally, hypothyroidism trends higher in the older persons\textsuperscript{14}. Autoimmune disease (Hashimoto’s thyroiditis)—also more common with age—exacerbates the potential for hypothyroidism\textsuperscript{15}. Another possible reason for the low prevalence of hypothyroidism in our study is the short disease duration of our patients compared to that of previous studies. The median duration of SSc in our study population was 4.9, while it was 8 years from the first non-Raynaud’s phenomenon symptom in the previous study\textsuperscript{7}. Longer disease duration might be associated with higher prevalence of hypothyroidism because of the increasing rate of thyroid gland fibrosis. Other reasons for the low prevalence of hypothyroidism in our study might be ethnic differences or genetic factors\textsuperscript{16}.

The prevalence of anemia among our participants was 10% in SSc (13.8% in Japan\textsuperscript{3}, 10–14% in the United States\textsuperscript{4,5}, and 9.4% in New Zealand\textsuperscript{6}). The difference in prevalence might be explained by differences in the mean age of participants among the studies. The mean age of our participants was 55.8 ± 10.7 years vs. 64.9 ± 0.7 years in a previous study\textsuperscript{3}. Generally, hypothyroidism in our study is the short disease duration of our patients compared to that of previous studies. The median duration of SSc in our study population was 4.9, while it was 8 years from the first non-Raynaud’s phenomenon symptom in the previous study\textsuperscript{7}. Longer disease duration might be associated with higher prevalence of hypothyroidism because of the increasing rate of thyroid gland fibrosis. Other reasons for the low prevalence of hypothyroidism in our study might be ethnic differences or genetic factors\textsuperscript{16}.

### Table 3. Logistic regression analysis of clinical parameter of SSc associated with clinical-subclinical hypothyroidism. CI: confidence interval; OR: odds ratio. *Statistically significant.

| Factor           | Crude OR (95%CI) | Adjusted OR (95%CI) | p-value |
|------------------|------------------|---------------------|---------|
| Female           | 2.30 (0.85–7.21) | 2.11 (0.78–5.71)    | 0.14    |
| Raynaud’s phenomenon | 0.25 (0.09–0.61) | 0.28 (0.11–0.66)*   | 0.004*  |
| Weight loss      | 0.28 (0.05–0.99) | 0.31 (0.08–1.10)    | 0.07    |
| Anemia           | 2.48 (1.03–6.27) | 2.74 (1.17–6.47)*   | 0.02*   |

The clinical features associated with clinical-subclinical hypothyroidism among SSc patients vary according to population-based studies\textsuperscript{15,16,9}. Some reported that severe skin tightness or anti-topoisomerase antibody (ATA)\textsuperscript{17}—which are associated with severe disease—are commonly detected in SSc patients with hypothyroidism,
Table 4. Comparison of prevalence and clinical features associated with clinical-subclinical hypothyroidism among SSc patients. dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; RP: Raynaud’s phenomenon; ACA: Anti-centromere antibody; CREST syndrome: calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia. anti-Tg: antithyroglobulin; anti-TPO: anti-thyroid peroxidase antibodies.

| Authors            | N  | Ethnic  | Overall | dcSSc | lcSSc | Clinical association                                                                 |
|--------------------|----|---------|---------|-------|-------|--------------------------------------------------------------------------------------|
| Toki et al.3       | 200| Thai    | 15.5%   | 71%   | 29.0% | High prevalence of clinical-subclinical hypothyroidism Low prevalence of RP in clinical-subclinical hypothyroidism |
| Gordon et al.5     | 56 | Pennsylvania | 14%     | 20%   | 80%   | High prevalence of ACA positivity, Sjogren’s syndrome, and severe facial skin sclerosis in AITD |
| Solanki et al.6    | 85 | New Zealand | 9.4%    |       |       | Positive for both anti-Tg and anti-TPO antibodies, with primary hypothyroidism          |
| Shahin et al.10    | 23 | Egyptian |         |       |       | Correlation between hand joint restriction of motion and hypothyroidism in SSc patients with disease duration over 3 years |
| Bagnato et al.9    | 105| Italian |         |       |       | Severe skin thickness by mRSS and high TSH level                                      |
| Marasini et al.34  | 40 | Italian |         |       |       | SSc patients with hypothyroidism had higher pulmonary arterial pressure over against SSc patients with hyperthyroidism (46 vs. 37 mmHg) |
| Danielides et al.35| 138| Grecian |         |       |       | High prevalence of anti-TPO in lcSSc                                                  |

While other researchers reported a high prevalence of a mild form of the disease (CREST syndrome)3 or anti-centromere antibody7 among patients with hypothyroidism. A comparison of the prevalence and associated clinical features of clinical-subclinical hypothyroidism in SSc patients found in the literature and our study are presented in Table 4. Per the literature review, a clinical association with hypothyroidism in SSc remains inconclusive.

The possible cause of hypothyroidism in SSc is claimed to be due to autoimmune thyroiditis (AITD), especially Hashimoto’s thyroiditis. The exact mechanism of autoimmune thyroiditis in SSc is not known, but it is thought that both genetic and environmental factors are involved and play roles vis-à-vis the presence of ATA in SSc patients26. Biddal et al.27 reported that the mechanisms of natural polyautoimmunity would play a role in the presence of autoantibodies and the loss of self-tolerance in the immune system. In addition, AITD is often present in patients with polyautoimmunity, so patients with AITD might have an increased risk of developing autoimmune diseases. A Colombian study included 1083 patients for investigation the cluster patterns of polyautoimmunity. The authors found that SSc was the most common disease that coexists with AITD (23%), followed by rheumatoid arthritis (21%), systemic lupus erythematosus (18%), and multiple sclerosis (9%)30.

Another study of 179 Italian SSc patients with 179 age- and gender-matched control subjects revealed a high incidence of new cases of hypothyroidism, thyroid dysfunction, and anti-thyroperoxidase antibody positivity in SSc patients with a respective incidence of 15.5, 21, and 11 per 1000 patient-years. The logistic regression analysis from the same study showed an association between borderline high TSH and anti-thyroperoxidase antibody positivity in SSc patients31. Although AITD is likely a cause of hypothyroidism in SSc, we were unable to test for thyroid antibody, so we cannot clarify the etiology of hypothyroidism in our SSc patients and cannot determine the respective prevalence of AITD.

Another possible mechanism of hypothyroidism in SSc would be related to fibrosis. A previous study reported on the association between high mRSS and high TSH level5. In it, Bagnato et al.9 reported that in an age- and sex-matched control autopsy series, 56 of the fatal SSc patients had histologic evidence of severe fibrosis of the thyroid glands (i.e., 14% vs. 2% of pathologic vs. serologic cases). All of thyroid tissue of SSc patients with hypothyroidism had fibrosis with some lymphocytic infiltration, and in 6 of 7 patients circulating anti-thyroglobulin antibody was also detected7. The authors concluded that the thyroid autoimmune process led to gland fibrosis and hypothyroidism in severe SSc patients5. Our study did not find any association between the severity of fibrosis and clinical-subclinical hypothyroidism despite the fact that the majority of our SSc patients had the severe form SSc (dcSSc). Thus, the fibrosis mechanism for hypothyroidism in our SSc remains in question.

Since our study analysed the clinical association with a screening thyroid function test, none of the patients had any symptoms of either hypothyroidism or hyperthyroidism. Further study on the clinical outcomes of subclinical hypothyroidism—particularly the progression to primary hypothyroidism and the morbidity and mortality in SSc patients who had primary hypothyroidism—is recommended to determine the clinicals to monitor and the treatment guidance.

Our study had limitations due to the nature of retrospective data collection. We were thus unable to perform some investigations involving or affected by thyroid disease including pulmonary function tests and echocardiography on the same date of the thyroid function test evaluation. The tests were, however, mostly performed within 3–6 months before/after the thyroid function test assessment. No thyroid antibody was tested, so we cannot provide data on autoimmune thyroiditis in our patients. There were some missing data of ATA and anti-centromere antibody (ACA). Because neither anti-topoisomerase I nor ACA can help differentiating the SSc subset in Thai SSc patients36, so the autoantibodies are not always tested as a routine investigation among Thai SSc. Specific autoantibodies of SSc other than ATA and ACA (anti-RNA polymerase III, anti-Th/To) were also tested in minority of the patients. Due to the low prevalence of other related autoantibodies among Thai SSc and no clinical relevance36, we did not analyse the thyroid hormone status with those antibodies. Finally, the findings of this study were analysed from a single center, the results might not be applicable to the entire Thai
population. Owing to the large study population and sample size calculation, there is a high level of confidence of the estimated prevalence of thyroid disease among Thai SSc patients. The preliminary data may provide a baseline for assisting in the evaluation of SSc patients and could be used for improving the care of SSc patients in daily practice.

**Conclusion**
Clinical-subclinical hypothyroidism is rare in SSc patients. It is associated with a high frequency of anemia and a low frequency of Raynaud’s phenomenon. Clinical-subclinical hypothyroidism should thus be considered in cases of unexplained anemia in SSc patients.

**Data availability**
Data and materials are available upon request.

Received: 16 May 2021; Accepted: 9 July 2021
Published online: 21 July 2021

**References**

1. Varga, I. & Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. *J. Clin. Investig.* **117**, 557–567 (2007).
2. Fallahi, P. *et al.* Associations between systemic sclerosis and thyroid diseases. *Front. Endocrinol.* **8**, 266 (2017).
3. Toki, S., Motegi, S., Yamada, K., Uchiyama, A. & Ishikawa, O. Demographic and clinical features of autoimmune thyroid disorder in Japanese patients with systemic sclerosis. *J. Dermatol.* **41**, 1053–1057 (2014).
4. Kahl, L. E., Medsger, T. A. & Klein, I. Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). *J. Rheumatol.* **13**, 103–107 (1986).
5. Gordon, M. B., Klein, I., Dekker, A., Rodnan, G. P. & Medsger, T. A. Thyroid disease in progressive systemic sclerosis: Increased frequency of glandular fibrosis and hypothyroidism. *Ann. Intern. Med.* **95**, 431–435 (1981).
6. Solanki, K. K., Al-Majmoei, M. & White, D. H. N. High prevalence of antithyroid antibodies in a New Zealand cohort of patients with systemic sclerosis. *J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskel. Dis.* **24**, 264–271 (2018).
7. Ferrera, F. *et al.* AIRE gene polymorphisms in systemic sclerosis associated with autoimmune thyroiditis. *Clin. Immunol. Orlando Fla* **122**, 13–17 (2007).
8. Ugurlu, S., Caglar, E., Yesim, T., Balci, H. & Tasan, E. Anti-Scl-70 antibodies in autoimmune hypothyroidism. *Arthritis Rheum.* **65**, 152–156 (2008).
9. Baghato, G. L. *et al.* Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: Translational association with Hashimoto’s thyroiditis. *Endocrine* **51**, 291–297 (2016).
10. Shahin, A. A., Abdoh, S. & Abdelrazik, M. Prolactin and thyroid hormones in patients with systemic sclerosis: Correlations with disease manifestations and activity. *J. Rheumatol.* **61**, 703–709 (2002).
11. van den Hoogen, F. *et al.* 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum.* **65**, 2737–2747 (2013).
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum.* **23**, 581–590 (1980).
13. Ranganathan, P., Pramesh, C. S. & Busye, M. Common pitfalls in statistical analysis: ‘P’ values, statistical significance and confidence intervals. *Perspect. Clin. Res.* **6**, 116–117 (2015).
14. Kostoglou-Athanassiou, I. & Ntales, K. Hypothyroidism—New aspects of an old disease. *Hippokratia* **14**, 82–87 (2010).
15. Mariotti, S. *et al.* Thyroid and other organ-specific autoantibodies in healthy ceritanerians. *Lancet* **339**, 1506–1508 (1992).
16. Louthrenoo, W. *et al.* Lack of CTGF*-945C/G dimorphism in Thai patients with systemic sclerosis. *Open Rheumatol. J.* **5**, 59–63 (2011).
17. Kosenli, A. *et al.* Anemia Frequency and Etiology in Primary Hypothyroidism (BioScientifica, 2009).
18. Kulkarni, V. K. & Iadav, D. U. A study of anemia in primary hypothyroidism. *Int. J. Adv. Med.* **4**, 383 (2017).
19. Wopereis, D. M. *et al.* The relation between thyroid function and anemia: A pooled analysis of individual participant data. *J. Clin. Endocrinol. Metab.* **103**, 3658–3667 (2018).
20. Antonijević, N., Nesović, M., Trbojević, B. & Milosević, R. Anemia in hypothyroidism. *J. Int. Med. Res.* **27**, 19–25 (1999).
21. Das, C. *et al.* Etiology of anemia in primary hypothyroid subjects in a tertiary care center in Eastern India. *Indian J. Endocrinol. Metab.* **16**, 3561–363 (2012).
22. Shagan, B. P. & Friedman, S. A. Raynaud’s phenomenon in hypothyroidism. *Angiology* **27**, 19–25 (1976).
23. Latewish, A. M. *et al.* Remission of Raynaud’s phenomenon after l-thyroxine therapy in a patient with hypothyroidism. *J. Endocrino- lin. Investig.* **15**, 49–51 (1992).
24. Yu, M. G. & Quisumbing, J. P. M. Limited cutaneous systemic sclerosis arising in a patient with Graves’ disease. *BMJ Case Rep.* **2017**, (2017).
25. Withrington, R. H. & Seifert, M. H. Hypothyroidism associated with mixed connective tissue disease and its response to steroid therapy. *Ann. Rheum. Dis.* **40**, 315–316 (1981).
26. Sipilä, R., Viitasalo, K. & Heikkilä, J. Hypothyroidism, Raynaud’s phenomenon, and acute myocardial infarction in a young woman. *Clin. Cardiol.* **6**, 304–306 (1983).
27. Etehad Tavakol, M., Fatemi, A., Karbalaei, A., Emrani, Z. & Erlandssoon, B. E. Nailfold capillaroscopy in rheumatic diseases: Which parameters should be evaluated? *BioMed Res. Int.* **2015**, e974530 (2015).
28. Chaker, L., Bianco, A. C., Jonklaas, J. & Peeters, R. P. Hypothyroidism. *Lancet Lond. Engl.* **390**, 1550–1562 (2017).
29. Bliddal, S., Nielsen, C. H. & Feldt-Rasmussen, U. Recent advances in understanding autoimmune thyroid disease: The tallest tree in the forest of polyautoimmunity. *F1000Research* **6**, 1776 (2017).
30. Rojas-Villarraga, A., Amaya-Amaya, J., Rodriguez-Rodriguez, A., Mantilla, R. D. & Anaya, J. M. Introducing polyautoimmunity: Secondary autoimmune diseases no longer exist. *Autoimmune Dis.* **2012**, E1198–E1202 (2013).
31. Antonelli, A. *et al.* Incidence of thyroid disorders in systemic sclerosis: Results from a longitudinal follow-up. *J. Clin. Endocrinol. Metab.* **98**, E1198–E1202 (2013).
32. Foocharoen, C. *et al.* Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. *Int. J. Rheum. Dis.* **19**, 312–320 (2016).
33. Foocharoen, C. *et al.* Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais. *Int. J. Rheum. Dis.* **20**, 1572–1581 (2017).
34. Marasini, B., Massarotti, M. & Coscutta, R. Thyroid function, pulmonary arterial hypertension and scleroderma. *Am. J. Med.* **118**, 322–323 (2005).
35. Danielides, S. et al. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. Scand. J. Rheumatol. 40, 299–303 (2011).

Acknowledgements
We thank (a) the Research and Graduate Studies, the Scleroderma Research Group and the Faculty of Medicine at Khon Kaen University for support, (b) the Publication Clinic at Khon Kaen University, and (c) Mr. Bryan Roderick Hamman under the aegis of the Publication Clinic, Khon Kaen University for assistance with the English-language presentation of the manuscript.

Author contributions
Y.P. did the data collection and drafted the manuscript. C.F. designed the study, proofread, and approved the final manuscript. M.M., S.C., A.M., S.S., and R.N. proofread the manuscript.

Funding
The study received funding support from the Faculty of Medicine, Khon Kaen University, Thailand (Grant number IN61249).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to C.F.

Reprints and permissions information
is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021